Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement